Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

Glund Stephan; Stangier Joachim; van Ryn Joanne; Schmohl Michael; Moschetti Viktoria; Haazen Wouter; De Smet Marina; Gansser Dietmar; Norris Stephen; Lang Benjamin; Reilly Paul; Kreuzer Joerg

首页> 外文期刊>Journal of the American College of Cardiology >Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

【24h】

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

机译：用伊达珠单抗逆转24小时后重启达比加群酯，并在健康志愿者中重新服用伊达珠单抗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the American College of Cardiology》 |2016年第13期|共4页
作者
Glund Stephan; Stangier Joachim; van Ryn Joanne; Schmohl Michael; Moschetti Viktoria; Haazen Wouter; De Smet Marina; Gansser Dietmar; Norris Stephen; Lang Benjamin; Reilly Paul; Kreuzer Joerg;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers [J] . Glund Stephan, Stangier Joachim, van Ryn Joanne, Journal of the American College of Cardiology . 2016,第13期

机译：用伊达珠单抗逆转24小时后重启达比加群酯，并在健康志愿者中重新服用伊达珠单抗
2. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial [J] . Glund Stephan, Stangier Joachim, Schmohl Michael, The Lancet . 2015,第9994期

机译：安达珠单抗逆转达比加群对健康男性志愿者抗凝作用的安全性，耐受性和功效：一项随机，安慰剂对照，双盲1期试验
3. Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window [J] . Gorana Vukorepa, Sabina Deve?ija, Miljenko Crnjakovi?, Turkish Journal of Emergency Medicine . 2020,第2期

机译：在治疗时间窗口结束时，在Dabigatran逆转Dabigatran的逆转后急性缺血性卒中成功静脉溶栓
4. PK/PD Modeling of Dabigatran Reversal by Idarucizumab in Nonclinical Studies and Predictions of Human Response [C] . Joshuaine Toth, Guanfa Gan, Joanne van Ryn PEGS . 2015

机译：Dabigatran逆转的PK / PD模型在非临床研究中的非临床研究和人类反应预测
5. Safety pharmacokinetics and pharmacodynamics of idarucizumab a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study [O] . Masahiro Yasaka, Ippei Ikushima, Akiko Harada, 2017

机译：依达珠单抗（一种特定的达比加群逆转剂）在健康的日本志愿者中的安全性药代动力学和药效学：一项随机研究
6. Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window [O] . Sabina Deveđija*, Gorana Vukorepa, Miljenko Crnjaković, 2020

机译：在治疗时间窗口结束时，在Dabigatran逆转Dabigatran的逆转后急性缺血性卒中成功静脉溶栓

Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers

著录项

相似文献

相关主题

期刊订阅